L -5-Hydroxytryptophan treatment of sleep terrors in children

European Journal of Pediatrics

Volumn 163, Issue 7, 2004, Pages 402-407

  Bruni, Oliviero ^a   Ferri, Raffaele ^b   Miano, Silvia ^b   Verrillo, Elisabetta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

Author keywords

Arousal disorders; L 5 Hydroxytryptophan; Serotoninergic system; Sleep terrors

Indexed keywords

5 HYDROXYTRYPTOPHAN;

ANAMNESIS; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; DRUG SCREENING; ELECTROENCEPHALOGRAPHY; EVALUATION; FEMALE; FOLLOW UP; HEALTH CENTER; HUMAN; HYPOTHESIS; INTERVIEW; MALE; METHODOLOGY; NEUROLOGIC EXAMINATION; NIGHTMARE; OUTCOMES RESEARCH; PATIENT REFERRAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECORDING; SLEEP; UNIVERSITY; WAKEFULNESS;

EID: 3142752100     PISSN: 03406199     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00431-004-1444-7     Document Type: Article

References (35)

1. Adrien J (1995) The serotoninergic system and sleep-wakefulness regulation. In: Kales A (ed) The pharmacology of sleep. Springer, Berlin Heidelberg New York, pp 91-116
2. American Sleep Disorders Association (1997) International classification of sleep disorders, revised: diagnostic and coding manual. American Sleep Disorders Association, Rochester, Minnesota
3. Balon R (1994) Sleep terror disorder and insomnia treated with trazodone: a case report. Ann Clin Psychiatry 6: 161-163
4. Bastuji H, De Villard R, Garde P, Challamel MJ (1991) High voltage monomorphic delta activity during sleep in children with pavor nocturnus or somnambulism, and in normal controls. Sleep Res 20A: 285
5. Cameron OG, Thyer BA (1985) Treatment of pavor nocturnus with alprazolam. J Clin Psychiatry 46: 504
6. Dahl RE (1992) The pharmacologic treatment of sleep disorders. Psychiatric Clin North Am 15: 161-178
7. Daniels SR, Hudson JI, Horwitz RI (1995) Epidemiology of potential association between L -tryptophan ingestion and eosinophilia-myalgia syndrome. J Clin Epidemiol 48: 1413-1427
8. De Giorgis G, Miletto R, Iannuccelli M, Camuffo M, Scerni S (1987) Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study -L-5-HTP versus placebo. Drugs Exp Clin Res 13: 425-433
9. DiMario FJ Jr, Emery ES III (1987) The natural history of sleep terrors. Clin Pediatr 26: 505-511
10. Driver H, Shapiro C (1993) Parasomnias. BMJ 306: 921-924
11. Espa F, Ondze B, Deglise P, Billiard M, Besset A (2000) Sleep architecture, slow wave activity, and sleep spindles in adult patients with sleepwalking and sleep terrors. Clin Neurophysiol 111: 929-939
12. Farinelli S, Mariani A, Grimaldi A, Mariani M, Iannessi A, De Rosa F (1991) Eosinophilia-myalgia syndrome associated with 5-OH-tryptophan. Description of a case. Recenti Prog Med 82: 381-384
13. Gijsman HJ, van Gerven JM, de Kam ML, Schoemaker RC, Pieters MS, Weemaes M, de Rijk R, van der Post J, Cohen AF (2002) Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. J Clin Psychopharmacol 22: 183-189
14. Guilleminault C, Palombini L, Pelayo R, Chervin RD (2003) Sleepwalking and sleep terrors in prepubertal children: what triggers them? Pediatrics 111: e17-e25
15. Imeri L, Mancia M, Bianchi S, Opp MR (2000) 5-hydroxytryptophan, but not L -tryptophan, alters sleep and brain temperature in rats. Neuroscience 95: 445-452
16. Jacos BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72: 165-229
17. Kaufman J, Birmaher B, Perel J, Dahl RE, Stull S, Brent D, Trubnick L, Al-Shabbout M, Ryan ND (1998) Serotonergic functioning in depressed abused children: clinical and familial correlates. Biol Psychiatry 44: 973-981
18. Klarskov K, Johnson KL, Benson LM, Cragun JD, Gleich GJ, Wrona M, Jiang X-R, Dryhurst G, Naylor S (2003) Structural characterization of a case-implicated contaminant, "peak x," in commercial preparations of 5-hydroxytryptophan. J Rheumatol 30: 89-95
19. Kohen DP, Mahowald MW, Rosen GM (1992) Sleep-terror disorder in children: the role of self-hypnosis in management. Am J Clin Hypn 34: 233-244
20. Lask B (1988) A novel and non-toxic treatment for sleep terrors. BMJ 297: 592
21. Michelson D, Page SW, Casey R, Trucksess MW, Love LA, Milstien S, Wilson C, Massaquoi SG, Crofford LJ, Hallett M et al (1994) An eosinophilia-myalgia syndrome related disorder associated with exposure to L -5-hydroxytryptophan. J Rheumatol 21: 2261-2265
22. Philen RM, Hill RH Jr, Flanders WD, Caudill SP, Needham L, Sewell L, Sampson EJ, Falk H, Kilbourne EM (1993) Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico. Am J Epidemiol 138: 154-159
23. Popoviciu L, Corfariu O (1983) Efficacy and safety of midazolam in the treatment of night terrors in children. Br J Clin Pharmacol 16[Suppl 1]: 97S-102S
24. Ramaekers VT, Senderek J, Haeusler M, Haering M, Abeling N, Zerres K, Bergmann C, Heimann G, Blau N (2001) A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa. Mol Genet Metab 73: 179-187
25. Reimao R, Lefevre AB (1982) Evaluation of flurazepam and placebo on sleep disorders in childhood. Arq Neuropsiquiatr 40: 1-13
26. Ribeiro CA (2000) L -5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. For the Portuguese Head Society. Headache 40: 451-456
27. Riemann D, Vorderholzer U (1998) Treatment of depression and sleep disorders. Significance of serotonin and L -tryptophan in pathophysiology and therapy. Fortschr Med 116: 40-42
28. Ryan ND, Birmaher B, Perel JM, Dahl RE, Meyer V, Al-Shabbout M, Iyengar S, Puig-Antich J (1992) Neuroendocrine response to L -5-hydroxytryptophan challenge in prepubertal major depression. Depressed vs normal children. Arch Gen Psychiatry 49: 843-851
29. Schneider-Helmert D, Spinweber CL (1986) Evaluation of L -tryptophan for treatment of insomnia: a review. Psychopharmacology 89: 1-7
30. Schruers K, van Diest R, Nicolson N, Griez E (2002) L -5-Hydroxytryptophan induced increase in salivary cortisol in panic disorder patients and healthy volunteers. Psychopharmacology 161: 365-369
31. Shapiro S (1996) Epidemiologic studies of the association of L -tryptophan with the eosinophilia-myalgia syndrome: a critique [see comments]. J Rheumatol Suppl 46: 44-58
32. Weissbluth M (1984) Is drug treatment of sleep terrors warranted? Am J Dis Child 138: 1086
33. Williamson BL, Klarskov K, Tomlinson AJ, Gleich GJ, Naylor S (1998) Problems with over-the-counter 5-hydroxy- L -tryptophan. Nat Med 4: 983
34. Wyatt RJ, Engelamn K, Kupfer DJ, Fram DH, Sjoerdsma A and Snyder F (1970) Effects of L -tryptophan (a natural sedative) on human sleep. Lancet 7678: 842-845
35. Zucconi M, Oldani A, Ferini-Strambi L, Smirne S (1995) Arousal fluctuations in non-rapid eye movement parasomnias: the role of cyclic alternating pattern as a measure of sleep instability. J Clin Neurophysiol 12: 147-154